Jii Bum Lee
Overview
Explore the profile of Jii Bum Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh S, Park S, Lee S, Lee E, Kim T, Choi S, et al.
Cell Rep Med
. 2025 Jan;
6(2):101929.
PMID: 39874964
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) pose therapeutic challenge due to limited response to EGFR tyrosine kinase inhibitors (TKIs). This study presents preclinical...
2.
Lee J, Choi S, Shim H, Park B, Lee C, Sudhaman S, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39732365
Introduction: Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB to IIIA NSCLC harboring EGFR mutations. The role of neoadjuvant osimertinib in the perioperative setting...
3.
Nam H, Jung S, Lee J, Kong J, Lim S
Thorac Cancer
. 2024 Dec;
16(2):e15522.
PMID: 39727172
Introduction: Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta-like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the...
4.
Kim D, Synn C, Lee W, Jo H, Lee C, Lee S, et al.
Mol Cancer Ther
. 2024 Dec;
24(3):354-369.
PMID: 39632711
Various combination therapies have been investigated to overcome the limitations of using immune checkpoint inhibitors. However, determining the optimal combination therapy remains challenging. To overcome the therapeutic limitation, we conducted...
5.
Shim J, Kim Y, Yuh T, Lee J, Kim H, Hong M, et al.
Lung Cancer (Auckl)
. 2024 Nov;
15:149-159.
PMID: 39494146
Purpose: Small-cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers and is characterized by a high recurrence rate, early metastasis, and poor prognosis. Before the FDA approved...
6.
Lin J, Horan J, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson M, et al.
Cancer Discov
. 2024 Sep;
14(12):2367-2386.
PMID: 39269178
Three generations of tyrosine kinase inhibitors (TKI) have been approved for anaplastic lymphoma kinase (ALK) fusion-positive non-small cell lung cancer. However, none address the combined need for broad resistance coverage,...
7.
8.
Lee J, Huang Y, Oya Y, Nutzinger J, LE Ang Y, Sooi K, et al.
Lung Cancer
. 2024 Jul;
194:107862.
PMID: 38959670
Despite the efficacy of immunotherapy in non-small cell lung cancer (NSCLC), the majority of the patients experience relapse with limited subsequent treatment options. Preclinical studies of various epithelial tumors, such...
9.
Ou S, Le X, Nagasaka M, Reungwetwattana T, Ahn M, Lim D, et al.
Lung Cancer (Auckl)
. 2024 Jun;
15:87-114.
PMID: 38938224
The year 2024 is the 20 anniversary of the discovery of activating epidermal growth factor receptor () mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been...
10.
Lee J, Ou S
Lung Cancer (Auckl)
. 2024 May;
15():81-85.
PMID: 38818015
Treatment strategies for post-epidermal growth factor receptor () tyrosine kinase inhibitor (TKI) therapy in -mutant non-small cell lung cancer (NSCLC) is an ongoing challenge. Previously, the IMPRESS trial comparing platinum...